Already a member? Become a member Register
PCSK9 Forum

rss LinkedIn News
rss LinkedIn Latest News Updates

Hot topics

What do you do after Statin? So many choices… what is yours?

What do you do after Statin? So many choices… what is yours?

Reports from the 19th Virtual Closed Scientific Expert Meeting of the Editorial Board  Anne Goldberg

read more »
Keynote – HDL and PCSK9: Going for a ride?

Keynote – HDL and PCSK9: Going for a ride?

Reports from the 19th Virtual Closed Scientific Expert Meeting of the Editorial Board  Manuel Mayr

read more »
PCSK9 targeting: Inside versus outside?

PCSK9 targeting: Inside versus outside?

Reports from the 19th Virtual Closed Scientific Expert Meeting of the Editorial Board  Alberto Corsini

read more »
Statins and PCSK9 inhibitors in combination: Initial therapy in very high-risk patients in secondary prevention

Statins and PCSK9 inhibitors in combination: Initial therapy in very high-risk patients in secondary prevention

Reports from the 18th Virtual Closed Scientific Expert Meeting of the Editorial Board  Alberto Zambon 

read more »
Elevated LDL-C and elevated Lp(a) with recurrent MACE: What to do, to do what?

Elevated LDL-C and elevated Lp(a) with recurrent MACE: What to do, to do what?

Reports from the 18th Virtual Closed Scientific Expert Meeting of the Editorial Board  Erik Stroes 

read more »
Aortic valve stenosis: A key pathophysiological role for Lp(a)?

Aortic valve stenosis: A key pathophysiological role for Lp(a)?

Reports from the 18th Virtual Closed Scientific Expert Meeting of the Editorial Board  Benoit Arsenault 

read more »
Lp(a) and plaque progression: Insights from imaging

Lp(a) and plaque progression: Insights from imaging

Reports from the 18th Virtual Closed Scientific Expert Meeting of the Editorial Board  Marc Dweck 

read more »
LDL-C lowering with PCSK9 inhibition: Multi-modal imaging and impact on coronary plaque in ACS patients

LDL-C lowering with PCSK9 inhibition: Multi-modal imaging and impact on coronary plaque in ACS patients

Reports from the 18th Virtual Closed Scientific Expert Meeting of the Editorial Board  Stephen Nicholls 

read more »
siRNA-mediated lowering of Lp(a) by Olpasiran

siRNA-mediated lowering of Lp(a) by Olpasiran

Reports from the 17th Virtual Closed Scientific Expert Meeting of the Editorial Board  Michael Koren 

read more »
A new ASO PCSK9 inhibitor: The Etesian study

A new ASO PCSK9 inhibitor: The Etesian study

Reports from the 17th Virtual Closed Scientific Expert Meeting of the Editorial Board  Alexis Hofherr 

read more »
ASO-mediated reduction in Lp(a) levels: Update on Pelacarsen

ASO-mediated reduction in Lp(a) levels: Update on Pelacarsen

Reports from the 17th Virtual Closed Scientific Expert Meeting of the Editorial Board  Sotirios Tsimikas 

read more »
siRNA-mediated lowering of Lp(a) by SLN360

siRNA-mediated lowering of Lp(a) by SLN360

Reports from the 17th Virtual Closed Scientific Expert Meeting of the Editorial Board  Steve Nissen 

read more »
PCSK9 and diabetes risk

PCSK9 and diabetes risk

Reports from the 17th Virtual Closed Scientific Expert Meeting of the Editorial Board  Wilfried Le Goff 

read more »
Keynote: Clinical utility of cIMT in determining management of children with heFH and of CTCA in determining treatment effects in children with hoFH

Keynote: Clinical utility of cIMT in determining management of children with heFH and of CTCA in determining treatment effects in children with hoFH

Reports from the 17th Virtual Closed Scientific Expert Meeting of the Editorial Board  Albert Wiegman 

read more »
How much reduction of Lp(a) is needed to translate into major clinical benefit? Setting the scene: Focus on PCSK9 inhibitors

How much reduction of Lp(a) is needed to translate into major clinical benefit? Setting the scene: Focus on PCSK9 inhibitors

Reports from the 17th Virtual Closed Scientific Expert Meeting of the Editorial Board  Pia Kamstrup 

read more »
Keynote: PCSK9 gene variants –  An update

Keynote: PCSK9 gene variants – An update

Reports from the 16th Virtual Closed Scientific Expert Meeting of the Editorial Board  Marianne Abi-Fadel 

read more »
PCSK9 inhibitors in type 2 diabetes: New insights from clinical trials and epidemiologic and genetic data

PCSK9 inhibitors in type 2 diabetes: New insights from clinical trials and epidemiologic and genetic data

Reports from the 16th Virtual Closed Scientific Expert Meeting of the Editorial Board  Lawrence Leiter 

read more »
Keynote – History of PCSK9

Keynote – History of PCSK9

Reports from the 15th Virtual Closed Scientific Expert Meeting of the Editorial Board  Professor Nabil Seidah 

read more »
Keynote – How does LDL lowering stabilize vulnerable plaques?

Keynote – How does LDL lowering stabilize vulnerable plaques?

Reports from the 15th Virtual Closed Scientific Expert Meeting of the Editorial Board  Professor Peter Libby 

read more »
Is a ‘once-and-done’ approach to LDL lowering feasible?

Is a ‘once-and-done’ approach to LDL lowering feasible?

Reports from the 15th Virtual Closed Scientific Expert Meeting of the Editorial Board  Professor Kiran Musunuru 

read more »